Caitlin Raymond: When to Use Albumin vs. Plasma, and Why the Timing Matters
Caitlin Raymond, a board-certified Clinical Pathologist and current Transfusion Medicine Fellow at the National Institutes of Health, shared on LinkedIn:
“The Overlooked Half of the Exchange
When we talk about plasma exchange, most discussions stop at what we’re removing — antibodies, paraproteins, cytokines. But that’s only half the story.
Replacement fluid is the other half — and it quietly dictates safety, hemostasis, and recovery.
The right choice isn’t just technical; it’s clinical judgment in action.
In my latest blog post, I break down:
- When to use albumin vs. plasma, and why the timing matters
- How combination strategies (like 50:50 albumin–FFP) can balance practicality and bleeding risk
- Common myths and misconceptions — including why “albumin is always safer” isn’t true
Real-world scenarios: TTP, transplant desensitization, AMR, and more
Read the full post here.
Choosing the replacement fluid isn’t just following a protocol — it’s the art within the algorithm.
ecause in apheresis, the machines may be automated, but judgment isn’t.”

Stay updated with Hemostasis Today.
-
Jul 21, 2026, 01:28Dhamirah Nazihah Mohd Nasiruddin: A Milestone in My Haemostasis and Thrombosis Journey at ISTH 2026
-
Jul 21, 2026, 00:55Anita Brikman on PPTA’s First-Half 2026 Achievements
-
Jul 21, 2026, 00:50Caitlin Raymond: Can Therapeutic Plasma Exchange Reduce Microplastics?
-
Jul 21, 2026, 00:46Yohei Hisada: Science, Collaboration, and New Beginnings at ISTH 2026
-
Jul 21, 2026, 00:41Ahmed Koriesh: Inside Our 2026 Stroke Simulation Lab
-
Jul 20, 2026, 21:17Connie Montgomery: Building Community Through the HFA Black Voices Summit
-
Jul 20, 2026, 21:15Leonie Bolt: Honored to Present on Coronary Artery Calcium Scoring in Hemophilia A at ISTH 2026
-
Jul 20, 2026, 21:12Mihir Jain: Can Gene Therapy Transform Hemophilia Care in India?
-
Jul 20, 2026, 21:10Mohammed W. Badri: Are We Doing Enough to Prevent Life-Threatening Bleeds in Children?